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Introduction
Macrophages play critical roles in the development of many vascular inflammatory diseases, including atherosclerosis and hypertension [1] . Angiotensin II (Ang II) is the major bioactive hormone peptide of rennin-angiotensin system, which functions mainly through angiotensin type 1 receptor (AT1R) and its downstream signals, such as mitogen-activated protein kinase (MAPK) pathways [2] . Moreover, Ang II plays an important role in regulating macrophages to induce the production of inflammatory cytokines during various pathological insults [3] . Recently, Li et al found that Ang II activates MAPK pathway in macrophages which promotes the expression of C-reactive protein [4] .
Early growth response protein 1 (Egr-1, also known as NGFI-A, zif268, krox-24, and TIS8), is a zinc finger transcription factor, and is rapidly up-regulated in many cell types in response to various stimuli, such as growth factors, cytokines, mechanical stimuli and oxidative stress [5] . Increasing evidence indicates that Egr-1 is a key master regulator to activate the expression of several genes involved in the development of cardiovascular disorders, including atherosclerosis, ischemic pathology, allograft rejection and cardiac hypertrophy [6] . However, the mechanism for Ang II to regulate Egr-1 expression in macrophages remains unclear.
Peroxisome proliferator-activated receptor-γ (PPAR-γ), a ligand-dependent transcriptional factor, is a member of nuclear hormone receptors which regulates target genes by binding PPAR response elements in their promoter regions. It was reported that PPAR-γ plays a critical role in morphogenesis, cell growth and differentiation, lipid and glucose metabolism [7] . PPAR-γ is also involved in many inflammatory diseases, such as hypertension, atherosclerosis, kidney dysfunction and cancer [8, 9] . 15-deoxy-△ 12, 14 -prostaglandin J2 (15d-PGJ 2 ) is a natural peroxisome proliferators-activated receptor-γ (PPAR-γ) ligand [10] . Several studies have shown that 15d-PGJ 2 can modulate the inflammatory response in various diseases, such as diabetes, atherosclerosis and acute pancreatitis [11] . Moreover, 15d-PGJ 2 treatment inhibits the activity of bone marrow-derived monocyte/macrophages in chronic liver injury [12] . However, it is still unknown whether 15d-PGJ 2 affects Ang IIinduced Egr-1 expression in macrophages.
In this study, we aimed to explore the effect of Ang II on Egr-1 expression and investigated whether 15d-PGJ 2 could modulate this process in macrophages. We demonstrated that Ang II markedly up-regulated the expression of Egr-1, and this effect was markedly blocked by the inhibitors of AT1R, JNK or ERK in macrophages. Moreover, 15d-PGJ 2 treatment markedly reduced Ang II-induced expression of Egr-1 and its gene targets and macrophage migration. Thus, the present study for the first time reveals that Ang II is capable of inducing the expression Egr-1 via AT1R/JNK/ERK signal pathway, and this effect was inhibited by 15d-PGJ 2 .
Materials and Methods

Antibodies and reagents
Dulbecco modified Eagle medium (DMEM), trypsin and fetal calf serum (FCS) were purchased from Hyclone (South Logan, UT). The anti-Egr-1, anti-AT1R, anti-AT2R and anti-β-actin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-phospho-p38, anti-p38, anti-phospho-JNK, anti-JNK, anti-phospho-ERK, anti-ERK and anti-mouse/anti-rabbit conjugated antibodies were from Cell Signaling Technology (Beverly, MA). The 15d-PGJ 2 was purchased from Cayman Chemical (Ann Arbor, MI). The Ang II, Eprosartan (inhibitor of AT1R), PD123319 (inhibitor of AT2 receptor), GW9662 (antagonist of PPAR-γ) and N-acetylcysteine (NAC, inhibitor of ROS production) were obtained from Sigma-Aldrich (St Louis, MO). SP600125 (JNK inhibitor), SB203580 (p38 MAPK inhibitor) and PD98059 (ERK inhibitor) were obtained from Calbiochem (La Jolla, CA). All other chemicals were from Sigma-Aldrich (St Louis, MO), unless specified otherwise. 
Cellular Physiology and Biochemistry
Cell culture and treatment Raw 264.7 cell line was purchased from ATCC and cultured in DMEM supplemented with 10% fetal calf serum, penicillin (100 U/ml), and streptomycin (100 mg/ml) at 37℃ under a humidified atmosphere of 95% air and 5% CO 2 . To investigate which receptor mediates Ang II-induced expression of Egr-1, cells were pretreated with various inhibitors, including Eprosartan, (1 μmol/L), PD123319 (1 μmol/L), SP600125 (10 μmol/L), PD98059 (10 μmol/L) and SB203580 (10 μmol/L) for 0.5 hour and then treated with Ang II (100 nmol/L) for the indicated time points.
Isolation of peritoneal macrophages 8-week-old male mice were injected intraperitoneally with 3% thioglycolate 3 days, peritoneal macrophages were then collected by peritoneal lavage with 10 ml of phosphate-buffered saline and centrifuged at 1,000 rpm for 10 min. Cells were then incubated with RPMI1640 media supplemented 10% fetal bovine serum on the 24-well plate for 1 hour and used for the experiments [13] .
Quantitative real-time PCR analysis
Total RNA was extracted from cultured cells with Trizol (Invitrogen). Specific primers used for quantitative real-time PCR (qPCR) assays were 5'-CAGTCCCATCTACT CGGCTG-3'(sense) and 5'-TGTGGAAACAGATAGTCAGGGAT-3' (anti-sense) for Egr-1, and others as described previously [14, 15] . qPCR was performed on an iQ5 Real-Time PCR Detection System (Bio-Rad Laboratories) according to the manufacturer's protocol [16] .
Western blot
The cells were lyzed with extraction buffer (50 mmol/L Tris-HCl pH 7.5, 0.5% Triton X-100, 0.5% NP40, 150 mmol/L NaCl, 2 mmol/L EDTA, 1 mmol/L NaF, 1 mmol/L PMSF, 1 mmol/L Na 3 VO 4 ) and protease inhibitors. Western blot analysis was performed as previously described. Fifty-sixty micrograms of proteins were separated by SDS-PAGE on a 10% gel and then transferred to a nitrocellulose membrane. The membranes were incubated with primary antibodies against Egr-1 (1:1000), AT1R (1:500), AT2R (1:500), JNK (1:500), ERK (1:1000), p38 MAPK (1:500) and β-actin (1:2000) overnight, then incubated with an HRP-conjugated secondary antibody for 1 hour. The bands were scanned, and densitometry analysis was performed with the software Image J 2x (National Institutes of Health, Bethesda, MD) [17] [18] [19] [20] . For the phospho-specific protein, we calculated the relative intensity for target proteins through dividing the absolute intensity of phosphorylated proteins by the absolute intensity of total target proteins or β-actin.
Cell migration assay
Cell migration was determined in Boyden chambers as described [21] . Briefly, cells were serumstarved for 8 hours and then exposed to 15d-PGJ 2 or vehicle (negative control) for 0.5 hour. Then 4×10 4 cells were seeded to the upper chamber. Cell migration was allowed to proceed for 16 hours at 37℃ in 5% CO 2 . Cells migrated to the lower surface of the filter were stained 1% crystal violet in 2% ethanol for 20 min, quantified by cell counting under a microscope by randomly choosing different views and taking average counting.
Statistical analysis
All data were expressed as mean ±SEM. Differences between groups were evaluated for statistical significance using a Student's t-test. P < 0.05 was considered statistically significant.
Results
Ang II enhances Egr-1 expression in macrophages
To determine the effect of Ang II on Egr-1 expression, RAW 264.7 cells were treated with Ang II for 0.5, 1, 2 and 4 hours after overnight starvation. Western bolt analysis showed that the expression of Egr-1 was significantly increased after Ang II treatment and peaked at 2 hours (Fig. 1A) . Moreover, this increased expression of Egr-1 was in a dosedependent manner (Fig. 1B) . These results indicate that Ang II can induce Egr-1 expression in microphages. Meng 
Ang II upregulates Egr-1 expression through AT1R
Ang II is known to regulate cells through the activation of angiotensin II type 1 and type 2 receptors (AT1R and AT2R) [22] . We then determined the effect of Ang II on the expression of AT1R and AT2R in both Raw264.7 cells and peritoneal macrophages. We found that Ang II treatment significantly increased the expression of AT1R but not AT2R in both cell types (Fig. 2A) . To determine which receptor is involved in the regulation of Egr-1 by Ang II, peritoneal cells were pretreated with Eprosartan (inhibitor of AT1R) and PD123319 (inhibitor of AT2R) for 0.5 hour and then stimulated with Ang II for additional 2 hours. As shown in Fig. 2B and C, Ang II-induced upregulation of Egr-1 mRNA and protein was significantly abolished by Eprosartan in macrophages, but not by PD123319. Moreover, the expression pattern of Egr-1 was confirmed in the RAW 264.7 (Fig. 2D) . These results suggest that Ang II induces Egr-1 expression through the activation of AT1R.
Ang II induces Egr-1 expression via the JNK and ERK pathways
Since MAPKs (including JNK, p38 and ERK) are the major downstream effectors of AT1R, we then examined the levels of JNK, p38 and ERK phosphorylation in RAW 264.7 cells after Ang II treatment at various time points. Consistent with previous reports [23] , we found that Ang II treatment markedly increased the levels of JNK, p38 and ERK phosphorylation, which peaked at 15 min (p38 MAPK and ERK) or 30 min (JNK) (Fig. 3A) , indicating that Ang II can induce the activation of JNK, p38 and ERK signaling pathways in macrophages.
To further determine which signaling pathway contributes to Ang II-induced Egr-1 expression, RAW 264.7 cells were pretreated with specific MAPK inhibitors, including SP600125 (a JNK inhibitor), SB203580 (a p38 MAPK inhibitor) and PD98059 (a ERK inhibitor) for 0.5 hour and then stimulated with Ang II for additional 2 hours. As shown in Fig. 3B , SP600125 and PD98059 significantly abolished Ang II-induced expression of Egr-1, whereas SB203580 had the opposite effect.
15d-PGJ2 suppresses Ang II-induced Egr-1 expression via PPAR-γ activation and ROS formation
It is known that PPAR-γ is expressed in macrophages in response to Egr-1-dependent inflammation [12] . We then determined whether the activation of PPAR-γ can regulate The expression of Egr-1 was determined by qPCR analysis (A) and Western bolt analysis (B). The intensity of protein bands was quantified (bottom). Data are expressed as mean ± SEM (n=3). *P < 0.05 versus control.
# P < 0.05 versus Ang II alone. 
Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
15d-PGJ2 inhibits the expression of Egr-1-mediated inflammatory cytokines in macrophage after Ang II stimulation
Egr-1 is an initial factor of inflammation [24] . Ang II can increase the expression of inflammatory gene targets of Egr-1 in macrophages. We next examined whether the activation of PPAR-γ can affect the expression of Egr-1-meidated inflammatory genes. RAW 264.7 cells were pretreated with 15d-PGJ 2 for 0.5 hour and then stimulated with Ang II for additional 2 hours. 15d-PGJ 2 treatment significantly inhibited the Ang II-induced up-regulation of IL-1β, TNF-α, TGF-β, MCP-1 and ICAM mRNA expression (Fig. 5) . Together, these data indicate that 15d-PGJ 2 can inhibit Egr-1-mediated inflammatory response in macrophages.
15d-PGJ2 reduces macrophage migration and proliferation after Ang II stimulation 15d-PGJ 2 has also been reported to play an important role in regulating the migration of inflammatory cells [21] . Therefore, we examined the effect of 15d-PGJ 2 on Ang IIinduced macrophage migration and proliferation. A trans-well migration assay showed that treatment of macrophages with 15d-PGJ 2 markedly decreased Ang II-induced migration of macrophages (Fig. 6A,) . MTT analysis further indicated that 15d-PGJ 2 significantly reduced macrophage proliferation induced by Ang II (Fig. 6B ).
Discussion
In this study, we for the first time demonstrated that Ang II stimulation drastically increased Egr-1 expression in macrophages. This effect was mainly mediated via AT1R/JNK/ ERK signaling pathways. Moreover, 15d-PGJ 2 , a natural PPAR-γ ligand, markedly reduced Ang II-induced expression of Egr-1 and its inflammatory gene targets as well as macrophage migration.
Egr-1 is known as the master transcription factor that plays a critical role in regulating cell proliferation, differentiation and apoptosis. It is rapidly and transiently expressed in many cell types in response to various stimuli [25] . For example, hypoxia rapidly induces Egr-1 expression in mononuclear phagocytes [26] . Importantly, Egr-1 has been implicated in the pathophysiology of several vascular diseases. Inhibition of its activity by siRNA or [27] . In addition, knockout of Egr-1 markedly reduces the development of atherogenesis [28] . However, how Ang II regulates Egr-1 in macrophages is still unknown. In this study, our data showed that Ang II dramatically increased Egr-1 expression (Fig. 1) , and this effect was abolished by the inhibitors of AT1R, JNK and ERK ( Fig. 2 and 3) . Collectively, these data suggest that the activation of AT1R/JNK/ERK signaling pathways is required for Ang II-induced expression of Egr-1 in macrophages. PPAR-γ, a member of the nuclear receptor superfamily, is mainly found in adipocytes and functions in regulating adipocyte differentiation and glucose homeostasis [29] . Several studies demonstrated that PPAR-γ can be dramatically induced in monocytes/macrophages and T cells by inflammatory cytokines [29] . Increasing evidence suggests that a natural PPARγ agonist 15d-PGJ 2 is a key anti-inflammatory mediator [30] , and the anti-inflammatory action is mediated through either PPAR-γ-dependent or independent pathways [31] . For example, 15d-PGJ 2 regulates the expression of TNF-α and MCP-1 in bone marrow-derived monocytes/ macrophages via a PPAR-γ-dependent manner [21] . Furthermore, NF-κB is implicated in the inhibitory effects of 15d-PGJ2 on the inflammatory response [32] . However, little is known about the effect of 15d-PGJ 2 on the expression of Egr-1 and its target genes. Accumulating evidence indicates that Egr-1 is a zinc-finger transcription factor that can bind to the consensus DNA sequence GCG[T/G]GGGCG in the promoter and enhancer regions of many genes. It induces the expression of many inflammatory genes, such as IL-1β, TNF-α, MCP-1 and ICAM as well as procoagulant genes [26, 33] . Our results here showed that 15d-PGJ 2 treatment markedly reduced Ang II-induced expression of Egr-1 as well as the expression of IL-1β, TNF-α, TGF-β, MCP-1 and ICAM in macrophages, and PPAR-γ inhibitor GW9662 or ROS inhibitor NAC markedly abolished these effects (Fig. 4) . Thus these results suggest that the inhibitory effect of 15d-PGJ 2 on Egr-1 is partially via PPAR-γ and ROS production.
In conclusion, our results demonstrated that Ang II markedly enhanced Egr-1 expression in macrophages via AT1R/JNK/ERK signaling pathways. 15d-PGJ 2 significantly inhibits the expression of Egr-1 and its downstream targets as well as macrophage migration partially through activation of PPAR-γ and ROS pathways. Thus, the present study has identified a novel mechanism of Ang II-regulated Egr1 expression, which may provide a new therapeutic target for vascular inflammatory diseases.
